Law X.0 podcast

JW Verret on Bending Money Rules for Biotech

21.1.2020
0:00
20:12
Spol 15 sekunder tilbage
Spol 15 sekunder frem
Biotech firms have trouble getting reliable access to capital throughout the long, unpredictable development, testing, and approval process. While it’s in some ways a typical high risk, potentially high reward business, biotech can provide life-saving innovations when the success finally materializes.   J.W. Verret, GMU law school professor and member of the SEC’s investor advisory committee, has ideas to help biotech and other small-cap companies access the public and exempt markets more efficiently. Verret talks about why current securities regulations, like Reg A and Reg FD, hamper small-cap companies and hobble their search for liquidity. He discusses small changes, and better outreach from the SEC to small-cap firms, that could tip the scales and help match money with innovations that could improve lives.

Flere episoder fra "Law X.0"